E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
Characteristics of Sleep Disturbance in Patients with Long COVID: A Retrospective Observational Study in Japan.
Sunada, Naruhiko, Nakano, Yasuhiro, Otsuka, Yuki et al. · Journal of clinical medicine · 2022 · DOI
Quick Summary
This study looked at sleep problems in 363 long COVID patients in Japan and found that about 16.5% had significant sleep disturbance. People infected during the Omicron wave were twice as likely to have sleep problems compared to those infected during the Delta wave. Patients with sleep disturbance also reported more fatigue, brain fog, headaches, and anxiety, and had abnormal stress hormone levels suggesting their bodies were under persistent stress.
Why It Matters
Sleep disturbance is a significant symptom in long COVID and shares overlapping pathophysiology with ME/CFS, including immune and endocrine dysfunction. Understanding that sleep problems correlate with neuroendocrine stress markers and variant-specific prevalence may help researchers identify underlying mechanisms and develop targeted treatments for post-viral fatigue disorders.
Observed Findings
Sleep disturbance prevalence was 24.8% in Omicron-infected patients versus 12.8% in Delta-infected patients (approximately 2-fold difference).
Among patients with sleep disturbance, 75% reported sleep-onset insomnia (difficulty falling asleep) compared to 6.7% with early-awakening insomnia.
Patients with sleep disturbance had significantly elevated plasma adrenocorticotropin (ACTH) and significantly reduced serum growth hormone levels.
Patients with sleep disturbance reported higher rates of concurrent fatigue, headache, concentration loss, anxiety, low-grade fever, and brain fog compared to those without sleep disturbance.
Mid-awakening insomnia was associated with brain fog symptoms.
Inferred Conclusions
Sleep disturbance in long COVID shows a viral variant-dependent pattern, with higher prevalence following Omicron infection, suggesting variant-specific pathogenic mechanisms.
Hypothalamic-pituitary axis dysregulation (evidenced by ACTH/growth hormone abnormalities) is associated with sleep disturbance in long COVID, indicating neuroendocrine involvement.
Sleep disturbance clusters with multiple neurological and systemic symptoms, suggesting a shared pathophysiological basis rather than isolated sleep dysfunction.
Remaining Questions
What is the longitudinal course of sleep disturbance in long COVID—does it resolve, persist, or worsen over time?
What This Study Does Not Prove
This study does not establish causality—it cannot prove that the Omicron variant directly causes sleep disturbance or that hormonal changes cause (rather than result from) sleep problems. The cross-sectional design captures only a single time point and cannot determine whether sleep disturbance precedes or follows other long COVID symptoms, nor can it account for recall bias in symptom reporting.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does the variant-specific prevalence difference reflect biological differences in viral pathogenesis or differences in symptom reporting/host factors between infection periods?
Can the identified hormonal abnormalities (ACTH elevation, growth hormone reduction) be used as biomarkers to predict treatment response or predict which patients will develop sleep disturbance?
What is the mechanistic relationship between the specific sleep phenotype (sleep-onset vs. mid-awakening) and the observed neuroendocrine abnormalities?